Nature's Sunshine Products (NATR) 10-Q 8 Aug 24 2024 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2024	Jul. 19, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-34483
Entity Registrant Name	NATURE’S SUNSHINE PRODUCTS, INC.
Entity Incorporation, State or Country Code	UT
Entity Tax Identification Number	87-0327982
Entity Address, Address Line One	2901 Bluegrass Boulevard
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Lehi
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84043
City Area Code	801
Local Phone Number	341-7900
Title of 12(b) Security	Common Stock, no par value
Trading Symbol	NATR
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		18,507,763
Entity Central Index Key	0000275053
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 68,695	$ 82,373
Accounts receivable, net of allowance for doubtful accounts of $138 and $142, respectively	11,290	8,827
Inventories	62,304	66,895
Prepaid expenses and other	9,747	7,722
Total current assets	152,036	165,817
Property, plant and equipment, net	44,832	45,000
Operating lease right-of-use assets	13,722	13,361
Investment securities - trading	890	747
Deferred income tax assets	14,704	15,064
Other assets	9,647	9,784
Total assets	235,831	249,773
Current liabilities:
Accounts payable	8,422	7,910
Accrued volume incentives and service fees	22,144	22,922
Accrued liabilities	22,994	33,162
Deferred revenue	2,217	1,794
Income taxes payable	3,911	6,418
Current portion of operating lease liabilities	3,961	4,547
Total current liabilities	63,649	76,753
Liability related to unrecognized tax benefits	935	312
Long-term portion of operating lease liabilities	11,390	10,376
Deferred compensation payable	890	747
Deferred income tax liabilities	1,164	1,401
Other liabilities	1,403	644
Total liabilities	79,431	90,233
Commitments and contingencies
Shareholders’ equity:
Common stock, no par value, 50,000 shares authorized, 18,508 and 18,875 shares issued and outstanding, respectively	114,014	119,694
Retained earnings	53,381	49,711
Noncontrolling interest	5,790	5,482
Accumulated other comprehensive loss	(16,785)	(15,347)
Total shareholders’ equity	156,400	159,540
Total liabilities and shareholders’ equity	$ 235,831	$ 249,773

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 138	$ 142
Common stock, no par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized (in shares)	50,000	50,000
Common stock, shares outstanding (in shares)	18,508	18,875
Common stock, shares issued (in shares)	18,508	18,875

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Net sales	$ 110,551	$ 116,548	$ 221,544	$ 225,182
Cost of sales	31,664	31,924	63,679	63,616
Gross profit	78,887	84,624	157,865	161,566
Operating expenses:
Volume incentives	34,693	35,314	68,263	68,442
Selling, general and administrative	38,557	42,273	79,341	85,915
Operating income	5,637	7,037	10,261	7,209
Other loss, net	(1,214)	(1,087)	(1,183)	427
Income before provision for income taxes	4,423	5,950	9,078	7,636
Provision for income taxes	2,935	3,273	5,100	3,706
Net income	1,488	2,677	3,978	3,930
Net income attributable to noncontrolling interests	139	255	308	648
Net income attributable to common shareholders	$ 1,349	$ 2,422	$ 3,670	$ 3,282
Basic and diluted net income per common share:
Basic earnings per share attributable to common shareholders (in dollars per share)	$ 0.07	$ 0.13	$ 0.20	$ 0.17
Diluted earnings per share attributable to common shareholders (in dollars per share)	$ 0.07	$ 0.12	$ 0.19	$ 0.17
Weighted average basic common shares outstanding (in shares)	18,647	19,293	18,737	19,073
Weighted average diluted common shares outstanding (in shares)	19,119	19,747	19,184	19,460

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement of Comprehensive Income [Abstract]
Net income	$ 1,488	$ 2,677	$ 3,978	$ 3,930
Foreign currency translation loss (net of tax)	254	(1,245)	(1,438)	(2,898)
Total comprehensive income	$ 1,742	$ 1,432	$ 2,540	$ 1,032

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Retained Earnings	Noncontrolling Interest	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2022		19,093
Beginning balance at Dec. 31, 2022	$ 147,047	$ 121,583	$ 34,635	$ 4,142	$ (13,313)
Increase (Decrease) in Shareholders' Equity
Share-based compensation expense	1,058	$ 1,058
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)		42
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	(165)	$ (165)
Repurchase of common stock (in shares)		(90)
Repurchase of common stock	(823)	$ (823)
Net income	1,253		860	393
Other comprehensive loss	(1,653)				(1,653)
Ending balance (in shares) at Mar. 31, 2023		19,045
Ending balance at Mar. 31, 2023	146,717	$ 121,653	35,495	4,535	(14,966)
Beginning balance (in shares) at Dec. 31, 2022		19,093
Beginning balance at Dec. 31, 2022	$ 147,047	$ 121,583	34,635	4,142	(13,313)
Increase (Decrease) in Shareholders' Equity
Repurchase of common stock (in shares)	(99)
Repurchase of common stock	$ (900)
Net income	3,930
Ending balance (in shares) at Jun. 30, 2023		19,098
Ending balance at Jun. 30, 2023	149,398	$ 122,902	37,917	4,790	(16,211)
Beginning balance (in shares) at Mar. 31, 2023		19,045
Beginning balance at Mar. 31, 2023	146,717	$ 121,653	35,495	4,535	(14,966)
Increase (Decrease) in Shareholders' Equity
Share-based compensation expense	1,437	$ 1,437
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)		62
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	(91)	$ (91)
Repurchase of common stock (in shares)		(9)
Repurchase of common stock	(97)	$ (97)
Net income	2,677		2,422	255
Other comprehensive loss	(1,245)				(1,245)
Ending balance (in shares) at Jun. 30, 2023		19,098
Ending balance at Jun. 30, 2023	$ 149,398	$ 122,902	37,917	4,790	(16,211)
Beginning balance (in shares) at Dec. 31, 2023	18,875	18,875
Beginning balance at Dec. 31, 2023	$ 159,540	$ 119,694	49,711	5,482	(15,347)
Increase (Decrease) in Shareholders' Equity
Share-based compensation expense	1,369	$ 1,369
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)		16
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	(152)	$ (152)
Repurchase of common stock (in shares)		(105)
Repurchase of common stock	(1,848)	$ (1,848)
Net income	2,490		2,321	169
Other comprehensive loss	(1,692)				(1,692)
Ending balance (in shares) at Mar. 31, 2024		18,786
Ending balance at Mar. 31, 2024	$ 159,707	$ 119,063	52,032	5,651	(17,039)
Beginning balance (in shares) at Dec. 31, 2023	18,875	18,875
Beginning balance at Dec. 31, 2023	$ 159,540	$ 119,694	49,711	5,482	(15,347)
Increase (Decrease) in Shareholders' Equity
Repurchase of common stock (in shares)	(453)
Repurchase of common stock	$ (7,700)
Net income	$ 3,978
Ending balance (in shares) at Jun. 30, 2024	18,508	18,508
Ending balance at Jun. 30, 2024	$ 156,400	$ 114,014	53,381	5,790	(16,785)
Beginning balance (in shares) at Mar. 31, 2024		18,786
Beginning balance at Mar. 31, 2024	159,707	$ 119,063	52,032	5,651	(17,039)
Increase (Decrease) in Shareholders' Equity
Share-based compensation expense	1,261	$ 1,261
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)		70
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	(434)	$ (434)
Repurchase of common stock (in shares)		(348)
Repurchase of common stock	(5,876)	$ (5,876)
Net income	1,488		1,349	139
Other comprehensive loss	$ 254				254
Ending balance (in shares) at Jun. 30, 2024	18,508	18,508
Ending balance at Jun. 30, 2024	$ 156,400	$ 114,014	$ 53,381	$ 5,790	$ (16,785)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 3,978	$ 3,930
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Provision for doubtful accounts	0	94
Depreciation and amortization	6,659	5,638
Non-cash lease expense	3,298	2,104
Share-based compensation expense	2,630	2,495
Deferred income taxes	(14)	(2,323)
Purchase of trading investment securities	(110)	0
Proceeds from sale of trading investment securities	40	54
Realized and unrealized gains on investments	(72)	(92)
Foreign exchange losses (gains)	1,543	(309)
Changes in assets and liabilities:
Accounts receivable	(2,960)	1,042
Inventories	3,112	1,626
Prepaid expenses and other current assets	(2,162)	(1,235)
Other assets	(598)	(87)
Accounts payable	409	520
Accrued volume incentives and service fees	(144)	2,882
Accrued liabilities	(7,993)	3,654
Deferred revenue	477	(811)
Lease liabilities	(3,215)	(2,040)
Income taxes payable	(2,251)	78
Liability related to unrecognized tax benefits	726	6
Deferred compensation payable	142	38
Net cash provided by operating activities	3,495	17,264
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment	(7,040)	(4,747)
Net cash used in investing activities	(7,040)	(4,747)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments of long-term debt	0	(637)
Proceeds from revolving credit facility	34,216	13,503
Principal payments of revolving credit facility	(34,216)	(13,503)
Payments related to tax withholding for net-share settled equity awards	(586)	(256)
Repurchase of common stock	(7,725)	(920)
Net cash used in financing activities	(8,311)	(1,813)
Effect of exchange rates on cash and cash equivalents	(1,822)	(1,766)
Net increase (decrease) in cash and cash equivalents	(13,678)	8,938
Cash and cash equivalents at the beginning of the period	82,373	60,032
Cash and cash equivalents at the end of the period	68,695	68,970
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes, net of refunds	8,144	5,129
Cash paid for interest	$ 115	$ 114

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation We are a natural health and wellness company primarily engaged in the manufacture and sale of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products directly to customers and to a sales force of independent consultants who use the products themselves or resell them to consumers. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of our financial information as of June 30, 2024, and for the three and six-month periods ended June 30, 2024 and 2023. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2024. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023. Use of Estimates The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities, in these financial statements and accompanying notes. Actual results could differ from these estimates and those differences could have a material effect on our financial position and results of operations. The significant accounting estimates inherent in the preparation of our financial statements include estimates associated with our determination of liabilities related to independent consultant incentives, the determination of income tax assets and liabilities, certain other non-income tax and value-added tax contingencies, and legal contingencies. In addition, significant estimates form the basis for allowances with respect to inventory valuations. Various assumptions and other factors enter into the determination of these significant estimates. The process of determining significant estimates takes into account historical experience and current and expected economic conditions. Noncontrolling Interests Noncontrolling interests changed as a result of the net income attributable to noncontrolling interests of $0.1 million and $0.3 million for the three and six months ended June 30, 2024, respectively. Net income attributable to the noncontrolling interests was $0.3 million and $0.6 million for the three and six months ended June 30, 2023, respectively. As of June 30, 2024 and December 31, 2023, noncontrolling interests were $5.8 million and $5.5 million, respectively. Recent Accounting Pronouncements In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU provides additional guidance on the improved reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. In addition, the amendments improve interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The amendments in this update were effective as of December 15, 2023. The adoption of this ASU did not have a significant impact on our Consolidated Financial Statements. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU provides additional guidance on the disclosure of income taxes on an annual basis and require all public business entities to disclose specific categories in the rate reconciliation, provide additional information on reconciling items, additional information about income taxes paid, and additional information about income tax expense from continuing operation. The amendments in this update are effective as of December 15, 2024. The adoption of this ASU is not expected to have a significant impact on our Consolidated Financial Statements.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2024
Inventory Disclosure [Abstract]
Inventories	Inventories The composition of inventories is as follows (dollar amounts in thousands): June 30, December 31, Raw materials $ 16,773 $ 18,301 Work in progress 1,152 1,218 Finished goods 44,379 47,376 Total inventories $ 62,304 $ 66,895

Investment Securities - Trading

Investment Securities - Trading	6 Months Ended
	Jun. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Investment Securities - Trading	Investment Securities - Trading Our trading securities portfolio totaled $0.9 million at June 30, 2024, and $0.7 million at December 31, 2023, and generated gains of $11,000 and $45,000 for the three months ended June 30, 2024 and 2023, respectively, and gains of $0.1 million and $0.1 million for the six months ended June 30, 2024 and 2023, respectively.

Revolving Credit Facility and O

Revolving Credit Facility and Other Obligations	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Revolving Credit Facility and Other Obligations	Revolving Credit Facility and Other Obligations On July 11, 2017, we entered into a revolving credit agreement with Bank of America, N.A., with a borrowing limit of $25.0 million (the “Credit Agreement”). On June 23, 2022, the Credit Agreement was amended to extend the term to mature on July 1, 2027 and allows for additional borrowings of $25.0 million or up to three separate increases of no less than $5.0 million each, subject to the lender's due diligence. The amendment to the Credit Agreement also modified the calculation of interest. Interest under the amended Credit Agreement is the greater of BSBY Daily Floating Rate or the Index Floor, plus 1.50 percent (6.89 percent as of June 30, 2024), and an annual commitment fee of 0.25 percent on the unused portion of the commitment. At June 30, 2024 and December 31, 2023, there was no outstanding balance under the Credit Agreement. The Credit Agreement contains customary financial covenants, including financial covenants relating to our solvency and leverage. In addition, the Credit Agreement restricts certain capital expenditures, lease expenditures, other indebtedness, liens on assets, guarantees, loans and advances, dividends, mergers, consolidations and transfers of assets except as permitted in the Credit Agreement. The Credit Agreement is collateralized by our manufacturing facility, accounts receivable, inventories and other assets. As of June 30, 2024, we were in compliance with the debt covenants set forth in the Credit Agreement.

Net Income Per Share

Net Income Per Share	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Net Income Per Share	Net Income Per Share Basic net income per common share (“Basic EPS”), is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share (“Diluted EPS”) reflects the potential dilution that could occur if stock options or other contracts to issue common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share. Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three and six months ended June 30, 2024 and 2023 (dollar and share amounts in thousands, except for per share information): Three Months Ended Six Months Ended 2024 2023 2024 2023 Net income attributable to common shareholders $ 1,349 $ 2,422 $ 3,670 $ 3,282 Basic weighted average shares outstanding 18,647 19,293 18,737 19,073 Basic earnings per share attributable to common shareholders $ 0.07 $ 0.13 $ 0.20 $ 0.17 Diluted shares outstanding: Basic weighted-average shares outstanding 18,647 19,293 18,737 19,073 Stock-based awards 472 454 447 387 Diluted weighted-average shares outstanding 19,119 19,747 19,184 19,460 Diluted earnings per share attributable to common shareholders $ 0.07 $ 0.12 $ 0.19 $ 0.17 Dilutive shares excluded from diluted-per-share amounts: Share-based awards 790 735 790 735 Anti-dilutive shares excluded from diluted-per-share amounts: Share-based awards — 77 — 102 Potentially dilutive shares excluded from diluted-per-share amounts include performance-based restricted stock units, for which certain metrics have not been achieved. Potentially anti-dilutive shares excluded from diluted-per-share amounts include both non-qualified stock options and unearned performance-based options to purchase shares of common stock with exercise prices greater than the weighted-average share price during the period and shares that would be anti-dilutive to the computation of diluted net income per share for each of the periods presented.

Capital Transactions

Capital Transactions	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Capital Transactions	Capital Transactions Dividends The declaration of future dividends is subject to the discretion of our Board of Directors and will depend upon numerous factors, including earnings, financial condition, restrictions imposed by any indebtedness that may be outstanding, cash requirements, future prospects and other factors deemed relevant by our Board of Directors. Share Repurchase Program On March 10, 2021, we announced a $15.0 million common share repurchase program. On March 8, 2022, we announced an amendment to the share repurchase program allowing the repurchase of an additional $30.0 million in common shares. The repurchases may be made from time to time as market conditions warrant and are subject to regulatory considerations. For the six months ended June 30, 2024 and 2023, we repurchased 453,000 and 99,000 shares of our common stock for $7.7 million and $0.9 million, respectively. At June 30, 2024, the remaining balance available for repurchases under the program was $9.9 million. Share-Based Compensation During the year ended December 31, 2012, our shareholders adopted and approved the Nature’s Sunshine Products, Inc. 2012 Stock Incentive Plan ("2012 Incentive Plan"). The 2012 Incentive Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. The Compensation Committee of the Board of Directors has authority and discretion to determine the type of award, as well as the amount, terms and conditions of each award under the 2012 Incentive Plan, subject to the limitations of the 2012 Incentive Plan. A total of 1,500,000 shares of our common stock were originally authorized for the granting of awards under the 2012 Incentive Plan. In 2015, our shareholders approved an amendment to the 2012 Incentive Plan, to increase the number of shares of common stock reserved for issuance by 1,500,000 shares. On May 5, 2021, our shareholders approved the Amended and Restated 2012 Stock Incentive Plan, which among other amendments, increased the number of shares of common stock reserved for issuance by 2,000,000 shares. The number of shares available for awards, as well as the terms of outstanding awards, are subject to adjustment as provided in the Amended and Restated 2012 Incentive Plan for stock splits, stock dividends, recapitalizations and other similar events. Stock Options Our outstanding stock options include time-based stock options, which vest over differing periods of time ranging from the date of issuance to up to 48 months from the option grant date, and performance-based stock options, which have already vested upon achieving operating income margins of six, eight and ten percent as reported in four of five consecutive quarters over the term of the options. Stock option activity for the six-month period ended June 30, 2024, is as follows (amounts in thousands, except per share information): Number of Weighted Average Weighted Average Options outstanding at December 31, 2023 75 $ 11.25 $ 3.85 Granted — — — Forfeited or canceled — — — Exercised — — — Options outstanding at June 30, 2024 75 $ 11.25 $ 3.85 There was no share-based compensation expense for the three- and six-month periods ended June 30, 2024 and 2023. As of June 30, 2024 and December 31, 2023, there was no unrecognized share-based compensation expense related to the grants described above. At June 30, 2024, the aggregate intrinsic value of outstanding and exercisable stock options to purchase 75,000 shares of common stock was $0.5 million. At December 31, 2023, the aggregate intrinsic value of outstanding and exercisable options to purchase 75,000 shares of common stock was $0.5 million. For the six months ended June 30, 2024 and 2023, no shares of common stock were issued upon the exercise of stock options. As of June 30, 2024 and December 31, 2023, we did not have any unvested stock options outstanding. Restricted Stock Units Our outstanding restricted stock units (“RSUs”), include time-based RSUs, which vest over differing periods of time ranging from 12 months to up to 36 months from the RSU grant date, as well as performance-based RSUs, which vest upon achieving targets relating to adjusted EBITDA growth, and/or stock price levels. RSUs granted to members of the Board of Directors contain a restriction period in which the shares are not issued until two years after vesting. At June 30, 2024 and December 31, 2023, there were 110,000 and 100,000 vested RSUs, respectively, granted to the Board of Directors with an accompanying restriction period. Restricted stock unit activity for the six-month period ended June 30, 2024, is as follows (amounts in thousands, except per share information): Number of Weighted Average Restricted Stock Units outstanding at December 31, 2023 1,342 $ 11.21 Granted 375 17.23 Forfeited (135) 14.89 Issued (124) 13.32 Restricted Stock Units outstanding at June 30, 2024 1,458 12.24 During the six-month period ended June 30, 2024, we granted 375,000 RSUs under the 2012 Incentive Plan to the Board of Directors, executive officers and other employees, which were comprised of time-based RSUs, and adjusted EBITDA performance-based RSUs. The time-based RSUs were issued with a weighted-average grant date fair value of $17.20 per share and vest in 12 monthly installments over a one year period from the grant date or in annual installments over a three-year period from the grant date. The adjusted EBITDA performance-based RSUs were issued with a weighted-average grant date fair value of $17.25 per share and vest upon achieving adjusted EBITDA targets and maintaining those targets over a four-quarter period from the grant date. Share-based compensation expense related to time-based RSUs for the three-month periods ended June 30, 2024 and 2023, was approximately $0.9 million and $1.1 million, respectively. Share-based compensation expense related to time-based RSUs for the six-month periods ended June 30, 2024 and 2023, was approximately $1.9 million and $1.9 million, respectively. As of June 30, 2024 and December 31, 2023, the unrecognized share-based compensation expense related to the grants described above, excluding incentive awards discussed below, was $4.1 million and $4.2 million, respectively. The remaining compensation expense is expected to be recognized over the weighted average period of approximately 0.8 years. Share-based compensation expense related to performance-based RSUs for the three-month periods ended June 30, 2024 and 2023, was $0.3 million and $0.3 million, respectively. Share-based compensation expense related to performance-based RSUs for the six-month periods ended June 30, 2024 and 2023, was $0.7 million and $0.6 million, respectively. Should we attain all the metrics related to performance-based RSU grants, we would recognize up to $7.8 million of potential share-based compensation expense. We currently expect to recognize an additional $3.2 million of that potential share-based compensation expense.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
Segment Information	Segment Information We have four business segments (Asia, Europe, North America, and Latin America and Other) based primarily upon the geographic region where each segment operates, as well as the internal organization of our officers and their responsibilities. The geographic segments operate under the Nature’s Sunshine Products and Synergy WorldWide® brands. The Latin America and Other segment includes our wholesale business in which we sell products to various locally-managed entities independent of the Company that we have granted distribution rights for the relevant market. Net sales for each segment have been reduced by intercompany sales as they are not included in the measure of segment profit or loss reviewed by the chief executive officer. We evaluate performance based on contribution margin by segment before consideration of certain inter-segment transfers and expenses. Reportable business segment information is as follows (dollar amounts in thousands): Three Months Ended Six Months Ended 2024 2023 2024 2023 Net sales: Asia $ 49,984 $ 54,875 $ 96,204 $ 101,220 Europe 21,602 21,236 43,898 42,641 North America 33,563 34,658 70,088 69,306 Latin America and Other 5,402 5,779 11,354 12,015 Total net sales 110,551 116,548 221,544 225,182 Contribution margin (1): Asia 23,557 26,899 45,213 48,850 Europe 6,458 6,130 14,500 12,666 North America 12,298 13,902 25,900 26,763 Latin America and Other 1,881 2,379 3,989 4,845 Total contribution margin 44,194 49,310 89,602 93,124 Selling, general and administrative expenses (2) 38,557 42,273 79,341 85,915 Operating income 5,637 7,037 10,261 7,209 Other income (loss), net (1,214) (1,087) (1,183) 427 Income before provision for income taxes $ 4,423 $ 5,950 $ 9,078 $ 7,636 _________________________________________ (1) Contribution margin consists of net sales less cost of sales and volume incentives expense. (2) Service fees in China totaled $3.8 million and $6.9 million for the three and six-month periods ended June 30, 2024, respectively, compared to $5.2 million and $8.9 million for the three and six-month periods ended June 30, 2023. These service fees are included in selling, general and administrative expenses. From an individual country/region perspective, the United States, Taiwan and South Korea comprise 10 percent or more of consolidated net sales for the three and six-month periods ended June 30, 2024 and 2023, as follows (dollar amounts in thousands): Three Months Ended Six Months Ended 2024 2023 2024 2023 Net sales: United States $ 30,948 $ 32,088 $ 64,636 $ 64,074 Taiwan 16,308 16,041 32,100 30,216 South Korea 13,449 13,832 25,070 25,072 Other 49,846 54,587 99,738 105,820 $ 110,551 $ 116,548 $ 221,544 $ 225,182 Net sales generated by each of our product lines is set forth below (dollar amounts in thousands): Three Months Ended Six Months Ended 2024 2023 2024 2023 Asia General health $ 19,131 $ 18,158 $ 35,125 $ 31,922 Immune 2,249 1,312 3,933 1,774 Cardiovascular 13,625 14,840 27,599 29,735 Digestive 7,707 11,564 16,296 20,986 Personal care 1,044 1,442 2,336 2,783 Weight management 6,228 7,559 10,915 14,020 49,984 54,875 96,204 101,220 Europe General health $ 9,534 $ 8,615 $ 19,336 $ 17,789 Immune 2,203 2,141 4,538 4,425 Cardiovascular 2,296 2,302 4,715 4,821 Digestive 5,947 6,331 11,860 12,069 Personal care 1,145 1,254 2,413 2,431 Weight management 477 593 1,036 1,106 21,602 21,236 43,898 42,641 North America General health $ 15,032 $ 15,857 $ 31,439 $ 31,390 Immune 3,540 3,732 7,985 8,053 Cardiovascular 3,757 3,761 7,741 7,349 Digestive 8,555 8,761 17,723 17,492 Personal care 1,581 1,634 3,153 3,098 Weight management 1,098 913 2,047 1,924 33,563 34,658 70,088 69,306 Latin America and Other General health $ 1,564 $ 1,600 $ 3,134 $ 3,237 Immune 594 668 1,317 1,412 Cardiovascular 401 433 883 899 Digestive 2,488 2,585 5,237 5,470 Personal care 270 341 545 692 Weight management 85 152 238 305 5,402 5,779 11,354 12,015 $ 110,551 $ 116,548 $ 221,544 $ 225,182 From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands): June 30, December 31, Property, plant and equipment: United States $ 39,569 $ 41,239 Other 5,263 3,761 Total property, plant and equipment, net $ 44,832 $ 45,000 Total assets per segment is set forth below (dollar amounts in thousands): June 30, December 31, Assets: Asia $ 98,164 $ 105,636 Europe 18,468 20,920 North America 112,667 116,052 Latin America and Other 6,532 7,165 Total assets $ 235,831 $ 249,773

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For the three months ended June 30, 2024 and 2023, our provision for income taxes, as a percentage of income before income taxes was 66.4 percent and 55.0 percent, respectively, compared with a U.S. federal statutory rate of 21.0 percent. For the six months ended June 30, 2024 and 2023, our provision for income taxes, as a percentage of income before income taxes was 56.2 percent and 48.5 percent, respectively, compared with a U.S. federal statutory rate of 21.0 percent. The difference between the effective tax rate and the U.S. federal statutory tax rate for the three and six months ended June 30, 2024, was primarily attributed to operations in foreign countries which are treated as a branch for US tax purposes and current year foreign losses that presently do not provide future tax benefit, partially offset by foreign tax credits. The difference between the effective tax rate and the U.S. federal statutory tax rate for the three and six months ended June 30, 2023, was primarily attributed to tax liability related to foreign operations which are treated as a branch for U.S. tax purposes as well as recording a valuation allowance against deferred tax assets which were expected to expire before utilization. The difference between the effective tax rate for the three and six months ended June 30, 2024, compared to June 30, 2023, was primarily caused by a decrease in the utilization of foreign tax credits in the current period. Our U.S. federal income tax returns for 2020 through 2022 are open to examination for federal tax purposes. We have several foreign tax jurisdictions with open tax years from 2018 through 2023. As of June 30, 2024 and December 31, 2023, we have accrued $0.9 million and $0.3 million, respectively, related to unrecognized tax positions net of offsetting tax attributes. Interim income taxes are based on an estimated annualized effective tax rate applied to the respective quarterly periods, adjusted for discrete tax items in the period in which they occur. Although we believe our tax estimates are reasonable, we can make no assurance that the final tax outcome of these matters will not be different from that which we have reflected in our historical income tax provisions and accruals. Such differences could have a material impact on our income tax provision and operating results in the period in which we make such determination.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Proceedings We are a party to various other legal proceedings and disputes in the United States and foreign jurisdictions. As of June 30, 2024 and December 31, 2023, accrued liabilities were $0.6 million and $0.5 million, respectively, related to the estimated outcome of these proceedings. In addition, we are a party to other litigation where there is a reasonable possibility that a loss may be incurred, but either the losses are not considered to be probable or we cannot at this time estimate the loss, if any; therefore, no provision for losses has been provided. We believe future payments related to these matters could range from $0 to approximately $0.3 million. Management cannot predict the ultimate outcome of these matters, individually or in the aggregate, or their resulting effect on our business, financial position, results of operations or cash flows as litigation and related matters are subject to inherent uncertainties, and unfavorable rulings could occur. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on our business, financial position, results of operations, or cash flows for the period in which the ruling occurs and/or future periods. We maintain product liability, general liability and excess liability insurance coverage. However, insurance may not continue to be available at an acceptable cost to us, such coverage may not be sufficient to cover one or more large claims, or the insurers may successfully disclaim coverage as to a pending or future claim. Non-Income Tax Contingencies We have reserved for certain state sales and use tax and foreign non-income tax contingencies based on the likelihood of an obligation in accordance with accounting guidance for probable loss contingencies. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount is recorded. We provide provisions for potential payments of tax to various tax authorities for contingencies related to non-income tax matters, including value-added taxes and sales tax. We provide provisions for U.S. state sales taxes in each of the states where we have nexus. As of June 30, 2024 and December 31, 2023, accrued liabilities were $0.2 million and $0.2 million, respectively, related to non-income tax contingencies. While we believe that the assumptions and estimates used to determine contingent liabilities are reasonable, the ultimate outcome of these matters cannot presently be determined. We believe future payments related to these matters could range from $0 to approximately $3.4 million.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The fair value of a financial instrument is the amount that could be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets are marked to bid prices and financial liabilities are marked to offer prices. Fair value measurements do not include transaction costs. A fair value hierarchy is used to prioritize the quality and reliability of the information used to determine fair values of each financial instrument. Categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is defined into the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of June 30, 2024 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices Significant Significant Total Investment securities - trading $ 890 $ — $ — $ 890 Total assets measured at fair value on a recurring basis $ 890 $ — $ — $ 890 The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of December 31, 2023 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices Significant Significant Total Investment securities - trading $ 747 $ — $ — $ 747 Total assets measured at fair value on a recurring basis $ 747 $ — $ — $ 747 Investment securities - trading — Our trading portfolio consists of various marketable securities that are valued using quoted prices in active markets. For the six months ended June 30, 2024 and for the year ended December 31, 2023, there were no fair value measurements using significant other observable inputs (Level 2) or significant unobservable inputs (Level 3). The carrying amounts reflected on the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to their short-term nature. The carrying value of our debt approximates fair value due to its recent acquisition and short maturity. During the six months ended June 30, 2024 and 2023, we did not have any re-measurements of non-financial assets at fair value on a nonrecurring basis subsequent to their initial recognition.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Revenue Recognition Net sales include sales of products and shipping and handling charges, net of estimates for product returns and any related sales incentives or rebates based upon historical information and current trends. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products. All revenue is recognized when we satisfy our performance obligations under the contract. We recognize revenue by transferring the promised products to the customer, with revenue recognized at shipping point, the point in time the customer obtains control of the products. The majority of our contracts have a single performance obligation and are short term in nature. Contracts with multiple performance obligations are insignificant. Sales taxes and value-added taxes in the United States and foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Amounts received for unshipped merchandise are recorded as deferred revenue. Amounts for membership fees are deferred and amortized as revenue over the life of the membership, primarily one year. A reserve for product returns is recorded based upon historical experience and current trends. We allow independent consultants to return the unused portion of products within ninety days of purchase if they are not satisfied with the product. In some of our markets, the requirements to return products are more restrictive. Amounts billed to customers for shipping and handling are reported as a component of net sales. Volume incentives and other sales incentives or rebates are a significant part of our direct sales marketing program and represent commission payments made to independent consultants. These payments are designed to provide incentives for reaching higher sales levels. The amount of volume incentive expense recognized is determined based upon the amount of qualifying purchases in a given month and recorded as volume incentive expense. Payments to independent consultants for sales incentives or rebates related to their own purchases are recorded as a reduction of revenue. Some payments for sales incentives are processed daily; while others, including rebates, are calculated monthly based upon qualifying sales. Disaggregation of Revenue Our products are grouped into six principal categories: general health, immune, cardiovascular, digestive, personal care and weight management. We have four business segments that are based primarily upon the geographic region where each segment operates. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy WorldWide® brands. See Note 7, Segment Information, for further information on our reportable segments and presentation of disaggregated revenue by reportable segment and product category. Practical Expedients and Exemptions We have made the accounting policy election to treat shipping and handling as a fulfillment activity rather than a promised service under Topic 606.

Basis of Presentation (Policies

Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation We are a natural health and wellness company primarily engaged in the manufacture and sale of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products directly to customers and to a sales force of independent consultants who use the products themselves or resell them to consumers.
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of our financial information as of June 30, 2024, and for the three and six-month periods ended June 30, 2024 and 2023. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2024. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities, in these financial statements and accompanying notes. Actual results could differ from these estimates and those differences could have a material effect on our financial position and results of operations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU provides additional guidance on the improved reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. In addition, the amendments improve interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The amendments in this update were effective as of December 15, 2023. The adoption of this ASU did not have a significant impact on our Consolidated Financial Statements. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU provides additional guidance on the disclosure of income taxes on an annual basis and require all public business entities to disclose specific categories in the rate reconciliation, provide additional information on reconciling items, additional information about income taxes paid, and additional information about income tax expense from continuing operation. The amendments in this update are effective as of December 15, 2024. The adoption of this ASU is not expected to have a significant impact on our Consolidated Financial Statements.
Revenue Recognition	Revenue Recognition Net sales include sales of products and shipping and handling charges, net of estimates for product returns and any related sales incentives or rebates based upon historical information and current trends. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products. All revenue is recognized when we satisfy our performance obligations under the contract. We recognize revenue by transferring the promised products to the customer, with revenue recognized at shipping point, the point in time the customer obtains control of the products. The majority of our contracts have a single performance obligation and are short term in nature. Contracts with multiple performance obligations are insignificant. Sales taxes and value-added taxes in the United States and foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Amounts received for unshipped merchandise are recorded as deferred revenue. Amounts for membership fees are deferred and amortized as revenue over the life of the membership, primarily one year. A reserve for product returns is recorded based upon historical experience and current trends. We allow independent consultants to return the unused portion of products within ninety days of purchase if they are not satisfied with the product. In some of our markets, the requirements to return products are more restrictive. Amounts billed to customers for shipping and handling are reported as a component of net sales. Volume incentives and other sales incentives or rebates are a significant part of our direct sales marketing program and represent commission payments made to independent consultants. These payments are designed to provide incentives for reaching higher sales levels. The amount of volume incentive expense recognized is determined based upon the amount of qualifying purchases in a given month and recorded as volume incentive expense. Payments to independent consultants for sales incentives or rebates related to their own purchases are recorded as a reduction of revenue. Some payments for sales incentives are processed daily; while others, including rebates, are calculated monthly based upon qualifying sales. Disaggregation of Revenue Our products are grouped into six principal categories: general health, immune, cardiovascular, digestive, personal care and weight management. We have four business segments that are based primarily upon the geographic region where each segment operates. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy WorldWide® brands. See Note 7, Segment Information, for further information on our reportable segments and presentation of disaggregated revenue by reportable segment and product category. Practical Expedients and Exemptions We have made the accounting policy election to treat shipping and handling as a fulfillment activity rather than a promised service under Topic 606.

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2024
Inventory Disclosure [Abstract]
Schedule of Composition of Inventories	The composition of inventories is as follows (dollar amounts in thousands): June 30, December 31, Raw materials $ 16,773 $ 18,301 Work in progress 1,152 1,218 Finished goods 44,379 47,376 Total inventories $ 62,304 $ 66,895

Net Income Per Share (Tables)

Net Income Per Share (Tables)	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three and six months ended June 30, 2024 and 2023 (dollar and share amounts in thousands, except for per share information): Three Months Ended Six Months Ended 2024 2023 2024 2023 Net income attributable to common shareholders $ 1,349 $ 2,422 $ 3,670 $ 3,282 Basic weighted average shares outstanding 18,647 19,293 18,737 19,073 Basic earnings per share attributable to common shareholders $ 0.07 $ 0.13 $ 0.20 $ 0.17 Diluted shares outstanding: Basic weighted-average shares outstanding 18,647 19,293 18,737 19,073 Stock-based awards 472 454 447 387 Diluted weighted-average shares outstanding 19,119 19,747 19,184 19,460 Diluted earnings per share attributable to common shareholders $ 0.07 $ 0.12 $ 0.19 $ 0.17 Dilutive shares excluded from diluted-per-share amounts: Share-based awards 790 735 790 735 Anti-dilutive shares excluded from diluted-per-share amounts: Share-based awards — 77 — 102

Capital Transactions (Tables)

Capital Transactions (Tables)	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Schedule of Stock Option Activity	Stock option activity for the six-month period ended June 30, 2024, is as follows (amounts in thousands, except per share information): Number of Weighted Average Weighted Average Options outstanding at December 31, 2023 75 $ 11.25 $ 3.85 Granted — — — Forfeited or canceled — — — Exercised — — — Options outstanding at June 30, 2024 75 $ 11.25 $ 3.85
Scheduled of Restricted Stock Unit Activity	Restricted stock unit activity for the six-month period ended June 30, 2024, is as follows (amounts in thousands, except per share information): Number of Weighted Average Restricted Stock Units outstanding at December 31, 2023 1,342 $ 11.21 Granted 375 17.23 Forfeited (135) 14.89 Issued (124) 13.32 Restricted Stock Units outstanding at June 30, 2024 1,458 12.24

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
Schedule of Reportable Business Segment Information	Reportable business segment information is as follows (dollar amounts in thousands): Three Months Ended Six Months Ended 2024 2023 2024 2023 Net sales: Asia $ 49,984 $ 54,875 $ 96,204 $ 101,220 Europe 21,602 21,236 43,898 42,641 North America 33,563 34,658 70,088 69,306 Latin America and Other 5,402 5,779 11,354 12,015 Total net sales 110,551 116,548 221,544 225,182 Contribution margin (1): Asia 23,557 26,899 45,213 48,850 Europe 6,458 6,130 14,500 12,666 North America 12,298 13,902 25,900 26,763 Latin America and Other 1,881 2,379 3,989 4,845 Total contribution margin 44,194 49,310 89,602 93,124 Selling, general and administrative expenses (2) 38,557 42,273 79,341 85,915 Operating income 5,637 7,037 10,261 7,209 Other income (loss), net (1,214) (1,087) (1,183) 427 Income before provision for income taxes $ 4,423 $ 5,950 $ 9,078 $ 7,636 _________________________________________ (1) Contribution margin consists of net sales less cost of sales and volume incentives expense.
Schedule of Consolidated Net Sales Revenue by Geographical Locations	From an individual country/region perspective, the United States, Taiwan and South Korea comprise 10 percent or more of consolidated net sales for the three and six-month periods ended June 30, 2024 and 2023, as follows (dollar amounts in thousands): Three Months Ended Six Months Ended 2024 2023 2024 2023 Net sales: United States $ 30,948 $ 32,088 $ 64,636 $ 64,074 Taiwan 16,308 16,041 32,100 30,216 South Korea 13,449 13,832 25,070 25,072 Other 49,846 54,587 99,738 105,820 $ 110,551 $ 116,548 $ 221,544 $ 225,182
Revenue from External Customers by Products and Services	Net sales generated by each of our product lines is set forth below (dollar amounts in thousands): Three Months Ended Six Months Ended 2024 2023 2024 2023 Asia General health $ 19,131 $ 18,158 $ 35,125 $ 31,922 Immune 2,249 1,312 3,933 1,774 Cardiovascular 13,625 14,840 27,599 29,735 Digestive 7,707 11,564 16,296 20,986 Personal care 1,044 1,442 2,336 2,783 Weight management 6,228 7,559 10,915 14,020 49,984 54,875 96,204 101,220 Europe General health $ 9,534 $ 8,615 $ 19,336 $ 17,789 Immune 2,203 2,141 4,538 4,425 Cardiovascular 2,296 2,302 4,715 4,821 Digestive 5,947 6,331 11,860 12,069 Personal care 1,145 1,254 2,413 2,431 Weight management 477 593 1,036 1,106 21,602 21,236 43,898 42,641 North America General health $ 15,032 $ 15,857 $ 31,439 $ 31,390 Immune 3,540 3,732 7,985 8,053 Cardiovascular 3,757 3,761 7,741 7,349 Digestive 8,555 8,761 17,723 17,492 Personal care 1,581 1,634 3,153 3,098 Weight management 1,098 913 2,047 1,924 33,563 34,658 70,088 69,306 Latin America and Other General health $ 1,564 $ 1,600 $ 3,134 $ 3,237 Immune 594 668 1,317 1,412 Cardiovascular 401 433 883 899 Digestive 2,488 2,585 5,237 5,470 Personal care 270 341 545 692 Weight management 85 152 238 305 5,402 5,779 11,354 12,015 $ 110,551 $ 116,548 $ 221,544 $ 225,182
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country	From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands): June 30, December 31, Property, plant and equipment: United States $ 39,569 $ 41,239 Other 5,263 3,761 Total property, plant and equipment, net $ 44,832 $ 45,000
Schedule of Segment Reporting Information	Total assets per segment is set forth below (dollar amounts in thousands): June 30, December 31, Assets: Asia $ 98,164 $ 105,636 Europe 18,468 20,920 North America 112,667 116,052 Latin America and Other 6,532 7,165 Total assets $ 235,831 $ 249,773

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Fair Value Assets Measured on Recurring Basis	The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of June 30, 2024 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices Significant Significant Total Investment securities - trading $ 890 $ — $ — $ 890 Total assets measured at fair value on a recurring basis $ 890 $ — $ — $ 890 The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of December 31, 2023 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices Significant Significant Total Investment securities - trading $ 747 $ — $ — $ 747 Total assets measured at fair value on a recurring basis $ 747 $ — $ — $ 747

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Increase (decrease) in noncontrolling interest	$ 100	$ 300	$ 300	$ 600
Noncontrolling interest	$ 5,790		$ 5,790		$ 5,482

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 16,773	$ 18,301
Work in progress	1,152	1,218
Finished goods	44,379	47,376
Total inventories	$ 62,304	$ 66,895

Investment Securities - Tradi_2

Investment Securities - Trading (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Trading securities portfolio	$ 890		$ 890		$ 747
Debt securities, trading, realized gains	$ 11	$ 45	$ 100	$ 100

Revolving Credit Facility and_2

Revolving Credit Facility and Other Obligations (Details) - Revolving credit facility - Bank of America Credit Agreement	Jun. 23, 2022 USD ($) borrowing	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jul. 11, 2017 USD ($)
Long-term debt
Maximum borrowing capacity				$ 25,000,000
Potential increase in maximum borrowing capacity	$ 25,000,000
Number of separate increases | borrowing	3
Potential increase in maximum borrowing capacity, per occurrence	$ 5,000,000
Margin on variable rate	1.50%
Effective interest rate		6.89%
Annual commitment fee	0.25%
Long-term line of credit		$ 0	$ 0

Net Income Per Share (Details)

Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Earnings Per Share [Abstract]
Net income attributable to common shareholders	$ 1,349	$ 2,422	$ 3,670	$ 3,282
Basic weighted average shares outstanding (in shares)	18,647	19,293	18,737	19,073
Basic earnings (loss) per share attributable to common shareholders (in dollars per share)	$ 0.07	$ 0.13	$ 0.20	$ 0.17
Diluted shares outstanding:
Basic weighted-average shares outstanding (in shares)	18,647	19,293	18,737	19,073
Stock-based awards (in shares)	472	454	447	387
Diluted weighted-average shares outstanding (in shares)	19,119	19,747	19,184	19,460
Diluted earnings (loss) per share attributable to common shareholders (in dollars per share)	$ 0.07	$ 0.12	$ 0.19	$ 0.17
Dilutive shares excluded from diluted-per-share amounts:
Share-based awards (in shares)	790	735	790	735
Anti-dilutive shares excluded from diluted-per-share amounts:
Share-based awards (in shares)	0	77	0	102

Capital Transactions - Narrativ

Capital Transactions - Narrative (Details)

3 Months Ended

6 Months Ended

12 Months Ended

May 05, 2021 shares

Jun. 30, 2024 USD ($) shares

Mar. 31, 2024 USD ($)

Jun. 30, 2023 USD ($)

Mar. 31, 2023 USD ($)

Jun. 30, 2024 USD ($) vestingInstallment $ / shares shares

Jun. 30, 2023 USD ($) shares

Dec. 31, 2015 shares

Dec. 31, 2023 USD ($) shares

Mar. 08, 2022 USD ($)

Mar. 10, 2021 USD ($)

Dec. 31, 2012 shares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock repurchase program, authorized amount

$ 30,000,000

$ 15,000,000

Repurchase of common stock (in shares) | shares

453,000

99,000

Repurchase of common stock

$ 5,876,000

$ 1,848,000

$ 97,000

$ 823,000

$ 7,700,000

$ 900,000

Stock repurchase program, remaining authorized repurchase amount

9,900,000

9,900,000

2012 Stock Incentive Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares authorized under the plan (in shares) | shares

1,500,000

Additional number of shares authorized under the plan (in shares) | shares

2,000,000

1,500,000

Stock options

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation expense

0

0

0

0

Unrecognized share-based compensation expense

$ 0

$ 0

$ 0

Options outstanding (in shares) | shares

75,000

75,000

75,000

Aggregate intrinsic value, outstanding

$ 500,000

$ 500,000

$ 500,000

Exercised (in shares) | shares

0

Exercised (in dollars per share) | $ / shares

$ 0

Weighted-average grant date fair value (in dollars per share) | $ / shares

$ 0

Time-based stock options | Maximum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

48 months

Performance based stock options operating income margins

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Operating income margin, one (percentage)

6%

Operating income margin, two (percentage)

8%

Operating income margin, three (percentage)

10%

Unvested stock options outstanding (in shares) | shares

0

0

0

Performance based stock options operating income margins | Minimum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

1 year

Performance based stock options operating income margins | Maximum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

1 year 3 months

RSUs

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation expense

$ 900,000

1,100,000

$ 1,900,000

$ 1,900,000

Unrecognized share-based compensation expense

$ 4,100,000

$ 4,100,000

$ 4,200,000

Weighted-average period over which the remaining compensation cost is expected to be recognized

9 months 18 days

Minimum withholding requirements (in shares) | shares

38,000

24,000

RSUs | 2012 Stock Incentive Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted (in shares) | shares

375,000

RSUs | Minimum | 2012 Stock Incentive Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

12 months

RSUs | Maximum | 2012 Stock Incentive Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

36 months

RSUs | Director | 2012 Stock Incentive Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Restriction period for issuance of shares

2 years

Nonvested subject to restriction period (in shares) | shares

110,000

110,000

100,000

Time-Based Restricted Stock Units (RSUs), 1-year Vesting | 2012 Stock Incentive Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

1 year

Weighted-average grant date fair value (in dollars per share) | $ / shares

$ 17.20

Number of vesting installments | vestingInstallment

12

Time-Based Restricted Stock Units (RSUs), 3-year Vesting | 2012 Stock Incentive Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

3 years

Adjusted EBITDA Performance-Based Restricted Stock Units | 2012 Stock Incentive Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period

1 year

Weighted-average grant date fair value (in dollars per share) | $ / shares

$ 17.25

Performance-Based Restricted Stock Units (RSUs)

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation expense

$ 300,000

$ 300,000

$ 700,000

$ 600,000

Share based compensation potential compensation expense to be recognized

3,200,000

3,200,000

Performance-Based Restricted Stock Units (RSUs) | Maximum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share based compensation potential compensation expense to be recognized

$ 7,800,000

$ 7,800,000

Capital Transactions - Stock Op

Capital Transactions - Stock Option Activity (Details) - Stock options	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Number of Shares
Options outstanding at the beginning of the period (in shares) | shares	75,000
Granted (in shares) | shares	0
Forfeited or canceled (in shares) | shares	0
Exercised (in shares) | shares	0
Options outstanding at the end of the period (in shares) | shares	75,000
Weighted Average Exercise Price Per Share
Options outstanding at the beginning of the period (in dollars per share)	$ 11.25
Granted (in dollars per share)	0
Forfeited or canceled (in dollars per share)	0
Exercised (in dollars per share)	0
Options outstanding at the end of the period (in dollars per share)	11.25
Weighted Average Grant Date Fair Value
Options outstanding at the beginning of the period (in dollars per share)	3.85
Granted (in dollars per share)	0
Forfeited or canceled (in dollars per share)	0
Exercised (in dollars per share)	0
Options outstanding at the beginning of the period (in dollars per share)	$ 3.85

Capital Transactions - RSU Acti

Capital Transactions - RSU Activity (Details) - 2012 Stock Incentive Plan - RSUs	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Number of Shares
Restricted stock units outstanding, beginning balance (in shares) | shares	1,342,000
Granted (in shares) | shares	375,000
Forfeited (in shares) | shares	(135,000)
Issued (in shares) | shares	(124,000)
Restricted stock units outstanding, ending balance (in shares) | shares	1,458,000
Weighted Average Grant Date Fair Value
Restricted stock units outstanding, beginning balance (in dollars per share) | $ / shares	$ 11.21
Granted (in dollars per share) | $ / shares	17.23
Forfeited (in dollars per share) | $ / shares	14.89
Issued (in dollars per share) | $ / shares	13.32
Restricted stock units outstanding, ending balance (in dollars per share) | $ / shares	$ 12.24

Segment Information (Details)

Segment Information (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) segment	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Segment information
Number of business segments | segment			4
Net sales:
Total net sales revenue	$ 110,551	$ 116,548	$ 221,544	$ 225,182
Contribution margin:
Total contribution margin	44,194	49,310	89,602	93,124
Selling, general and administrative expenses	38,557	42,273	79,341	85,915
Operating income	5,637	7,037	10,261	7,209
Other income (loss), net	(1,214)	(1,087)	(1,183)	427
Income before provision for income taxes	4,423	5,950	9,078	7,636
Total property, plant and equipment, net	44,832		44,832		$ 45,000
Total assets	235,831		235,831		249,773
China
Contribution margin:
Selling, general and administrative expenses	3,800	5,200	6,900	8,900
United States
Net sales:
Total net sales revenue	30,948	32,088	64,636	64,074
Contribution margin:
Total property, plant and equipment, net	39,569		39,569		41,239
Taiwan
Net sales:
Total net sales revenue	16,308	16,041	32,100	30,216
South Korea
Net sales:
Total net sales revenue	13,449	13,832	25,070	25,072
Other
Net sales:
Total net sales revenue	49,846	54,587	99,738	105,820
Contribution margin:
Total property, plant and equipment, net	5,263		5,263		3,761
Asia
Net sales:
Total net sales revenue	49,984	54,875	96,204	101,220
Contribution margin:
Total contribution margin	23,557	26,899	45,213	48,850
Total assets	98,164		98,164		105,636
Asia | General health
Net sales:
Total net sales revenue	19,131	18,158	35,125	31,922
Asia | Immune
Net sales:
Total net sales revenue	2,249	1,312	3,933	1,774
Asia | Cardiovascular
Net sales:
Total net sales revenue	13,625	14,840	27,599	29,735
Asia | Digestive
Net sales:
Total net sales revenue	7,707	11,564	16,296	20,986
Asia | Personal care
Net sales:
Total net sales revenue	1,044	1,442	2,336	2,783
Asia | Weight management
Net sales:
Total net sales revenue	6,228	7,559	10,915	14,020
Europe
Net sales:
Total net sales revenue	21,602	21,236	43,898	42,641
Contribution margin:
Total contribution margin	6,458	6,130	14,500	12,666
Total assets	18,468		18,468		20,920
Europe | General health
Net sales:
Total net sales revenue	9,534	8,615	19,336	17,789
Europe | Immune
Net sales:
Total net sales revenue	2,203	2,141	4,538	4,425
Europe | Cardiovascular
Net sales:
Total net sales revenue	2,296	2,302	4,715	4,821
Europe | Digestive
Net sales:
Total net sales revenue	5,947	6,331	11,860	12,069
Europe | Personal care
Net sales:
Total net sales revenue	1,145	1,254	2,413	2,431
Europe | Weight management
Net sales:
Total net sales revenue	477	593	1,036	1,106
North America
Net sales:
Total net sales revenue	33,563	34,658	70,088	69,306
Contribution margin:
Total contribution margin	12,298	13,902	25,900	26,763
Total assets	112,667		112,667		116,052
North America | General health
Net sales:
Total net sales revenue	15,032	15,857	31,439	31,390
North America | Immune
Net sales:
Total net sales revenue	3,540	3,732	7,985	8,053
North America | Cardiovascular
Net sales:
Total net sales revenue	3,757	3,761	7,741	7,349
North America | Digestive
Net sales:
Total net sales revenue	8,555	8,761	17,723	17,492
North America | Personal care
Net sales:
Total net sales revenue	1,581	1,634	3,153	3,098
North America | Weight management
Net sales:
Total net sales revenue	1,098	913	2,047	1,924
Latin America and Other
Net sales:
Total net sales revenue	5,402	5,779	11,354	12,015
Contribution margin:
Total contribution margin	1,881	2,379	3,989	4,845
Total assets	6,532		6,532		$ 7,165
Latin America and Other | General health
Net sales:
Total net sales revenue	1,564	1,600	3,134	3,237
Latin America and Other | Immune
Net sales:
Total net sales revenue	594	668	1,317	1,412
Latin America and Other | Cardiovascular
Net sales:
Total net sales revenue	401	433	883	899
Latin America and Other | Digestive
Net sales:
Total net sales revenue	2,488	2,585	5,237	5,470
Latin America and Other | Personal care
Net sales:
Total net sales revenue	270	341	545	692
Latin America and Other | Weight management
Net sales:
Total net sales revenue	$ 85	$ 152	$ 238	$ 305

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Provision (benefit) for income taxes, as a percentage of income before income taxes	66.40%	55%	56.20%	48.50%
Liability related to unrecognized tax benefits	$ 0.9		$ 0.9		$ 0.3

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Value-added tax assessments and other civil litigation
Commitments and contingencies
Provision for losses	$ 0
Non-Income Tax Contingencies
Commitments and contingencies
Accrued liabilities	200,000	$ 200,000
Minimum | Value-added tax assessments and other civil litigation
Commitments and contingencies
Estimate of possible loss	0
Minimum | Non-Income Tax Contingencies
Commitments and contingencies
Estimate of possible loss	0
Maximum | Value-added tax assessments and other civil litigation
Commitments and contingencies
Estimate of possible loss	300,000
Maximum | Non-Income Tax Contingencies
Commitments and contingencies
Estimate of possible loss	3,400,000
Pending Litigation
Commitments and contingencies
Accrued liabilities	$ 600,000	$ 500,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Recurring basis - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Total
Fair value
Investment securities - trading	$ 890	$ 747
Total assets measured at fair value on a recurring basis	890	747
Level 1 - Quoted Prices in Active Markets for Identical Assets
Fair value
Investment securities - trading	890	747
Total assets measured at fair value on a recurring basis	890	747
Level 2 - Significant Other Observable Inputs
Fair value
Investment securities - trading	0	0
Total assets measured at fair value on a recurring basis	0	0
Level 3 - Significant Unobservable Inputs
Fair value
Investment securities - trading	0	0
Total assets measured at fair value on a recurring basis	$ 0	$ 0

Revenue Recognition (Details)

Revenue Recognition (Details)	6 Months Ended
	Jun. 30, 2024 segment product_category
Revenue from Contract with Customer [Abstract]
Refund period	90 days
Number of principal categories of products | product_category	6
Number of business segments | segment	4